A Phase 4 interventional study of ADVATE in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 5 sites in India. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 4, and was the 20th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 1 started in 2022.
This study's enrollment of 50 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
47 studies in Hemophilia A by Takeda: none open now, 1 under way, none of them phase 3. Of 46 finished, 27 (59%) have results posted.
Among the 47 studies in Hemophilia A by Takeda, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 4, and was the 45th registered.
Takeda’s Hemophilia A studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 47 in Hemophilia A:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to learn more about side effects of Advate when given as standard treatment to people with hemophilia A who have already been treated.
The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. Participants will need to visit the study doctor 5 times in total during the study. During these visits, study data will be collected by the study doctor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant defined as a previously treated patient (PTP):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with hemophilia A were treated with ADVATE according to a regimen determined by the treating physician at the study site and in accordance with the national product label under standard clinical practice for 6.7 months.
Biological: ADVATE
Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
Number of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. An SAE was defined as any untoward medical occurrence that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of present hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was a medically important event. Number of participants with SAEs (including FVIII inhibitor formation) that were at least possibly related to ADVATE were reported.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Number of Participants With Non-serious Adverse Events (AEs) at Least Possibly Related to ADVATE
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. Number of participants with non-serious AEs that were at least possibly related to ADVATE were reported.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Clinical laboratory parameters included hematology, clinical chemistry, viral serology, factor VIII (FVIII) antigen, FVIII activity, incremental recovery, and FVIII inhibitor. Clinical significance was judged as per Investigator's assessment.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Total Annualized Bleeding Rate (ABR) With Prophylactic Treatment of ADVATE
ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error was estimated using a generalized linear model (GLM). The total ABR is reported in this outcome measure.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
ABR With Prophylactic Treatment of ADVATE Categorized Based on Location of Bleed
ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed sites (example, joint, soft tissue, muscle, other \[mouth, gums or nose\] are reported in this outcome measure.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
ABR With Prophylactic Treatment of ADVATE Categorized Based on Type of Bleed
ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed cause (example, spontaneous, injury, and unknown) are reported in this outcome measure.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Total Number of ADVATE Infusions Required During Prophylactic Treatment
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Average Number of ADVATE Infusions Required Per Week During Prophylactic Treatment
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Average Number of ADVATE Infusions Required Per Month During Prophylactic Treatment of Bleeding Episode
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Total Body Mass Adjusted Consumption of ADVATE During Prophylactic Treatment
Body mass adjusted consumption international units per kilograms (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Average Body Mass Adjusted Consumption of ADVATE Per Week During Prophylactic Treatment
Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Average Body Mass Adjusted Consumption of ADVATE Per Month During Prophylactic Treatment
Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Overall Hemostatic Efficacy Rating of ADVATE for Treatment of Bleeding Episodes
Overall hemostatic efficacy for treatment of bleeding episodes was rated on 4-point Likert scale as: excellent=full relief of pain and cessation of objective signs of bleeding after a single infusion, no additional infusion is required for the control of bleeding and administration of further infusion to maintain hemostasis would not affect the scoring; good=definite pain relief and/or improvement in signs of bleeding after a single infusion, possibly requires more than 2 infusions for complete resolution and administration of further infusion to maintain hemostasis would not affect the scoring; moderate=probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion, required multiple infusions for complete resolution; none=no improvement of signs or symptoms or conditions worsen.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Number of ADVATE Infusions Required to Achieve Resolution of Bleeding Episodes
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Total Body Mass Adjusted Consumption of ADVATE Per Bleeding Episode
Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)
Participants took part in the study at 4 investigative sites in India from 14 January 2022 to 10 February 2023.
| Milestone | Hemophilia A Group |
|---|---|
| Started | 50 |
| Completed | 49 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. An SAE was defined as any untoward medical occurrence that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of present hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was a medically important event. Number of participants with SAEs (including FVIII inhibitor formation) that were at least possibly related to ADVATE were reported.
| Participants | Hemophilia A Group |
|---|---|
| Number of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE | 0 |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. Number of participants with non-serious AEs that were at least possibly related to ADVATE were reported.
| Participants | Hemophilia A Group |
|---|---|
| Number of Participants With Non-serious Adverse Events (AEs) at Least Possibly Related to ADVATE | 0 |
Clinical laboratory parameters included hematology, clinical chemistry, viral serology, factor VIII (FVIII) antigen, FVIII activity, incremental recovery, and FVIII inhibitor. Clinical significance was judged as per Investigator's assessment.
| Participants | Hemophilia A Group |
|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | 0 |
ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error was estimated using a generalized linear model (GLM). The total ABR is reported in this outcome measure.
| bleeds per year | Hemophilia A Group |
|---|---|
| Total Annualized Bleeding Rate (ABR) With Prophylactic Treatment of ADVATE | 2.65 ± 0.195 |
ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed sites (example, joint, soft tissue, muscle, other \[mouth, gums or nose\] are reported in this outcome measure.
| bleeds per year | Hemophilia A Group |
|---|---|
| Bleed Location: Joint | 2.33 ± 0.203 |
| Bleed Location: Soft Tissue | 0.04 ± 1.000 |
| Bleed Location: Muscle | 0.16 ± 0.628 |
| Bleed Location: Other (Mouth, Gums or Nose) | 0.12 ± 0.813 |
ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed cause (example, spontaneous, injury, and unknown) are reported in this outcome measure.
| bleeds per year | Hemophilia A Group |
|---|---|
| Bleed Type: Spontaneous | 1.86 ± 0.211 |
| Bleed Type: Injury | 0.20 ± 0.692 |
| Bleed Type: Unknown | 0.59 ± 0.541 |
| infusions | Haemophilia A Group |
|---|---|
| Total Number of ADVATE Infusions Required During Prophylactic Treatment | 65.8 ± 22.92 |
| infusions per week | Hemophilia A Group |
|---|---|
| Average Number of ADVATE Infusions Required Per Week During Prophylactic Treatment | 2.5 ± 0.87 |
| infusions per month | Hemophilia A Group |
|---|---|
| Average Number of ADVATE Infusions Required Per Month During Prophylactic Treatment of Bleeding Episode | 11.0 ± 3.76 |
Body mass adjusted consumption international units per kilograms (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
| IU/kg | Hemophilia A Group |
|---|---|
| Total Body Mass Adjusted Consumption of ADVATE During Prophylactic Treatment | 1739.7 ± 621.18 |
Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
| IU/kg per week | Hemophilia A Group |
|---|---|
| Average Body Mass Adjusted Consumption of ADVATE Per Week During Prophylactic Treatment | 67.1 ± 24.12 |
Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
| IU/kg per month | Hemophilia A Group |
|---|---|
| Average Body Mass Adjusted Consumption of ADVATE Per Month During Prophylactic Treatment | 291.7 ± 104.80 |
Overall hemostatic efficacy for treatment of bleeding episodes was rated on 4-point Likert scale as: excellent=full relief of pain and cessation of objective signs of bleeding after a single infusion, no additional infusion is required for the control of bleeding and administration of further infusion to maintain hemostasis would not affect the scoring; good=definite pain relief and/or improvement in signs of bleeding after a single infusion, possibly requires more than 2 infusions for complete resolution and administration of further infusion to maintain hemostasis would not affect the scoring; moderate=probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion, required multiple infusions for complete resolution; none=no improvement of signs or symptoms or conditions worsen.
| bleeding episodes | Hemophilia A Group |
|---|---|
| Excellent | 21 |
| Good | 26 |
| Moderate | 4 |
| None | 0 |
| infusions | Hemophilia A Group |
|---|---|
| Number of ADVATE Infusions Required to Achieve Resolution of Bleeding Episodes | 1.2 ± 0.46 |
Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.
| IU/kg | Hemophilia A Group |
|---|---|
| Total Body Mass Adjusted Consumption of ADVATE Per Bleeding Episode | 34.8 ± 19.79 |
Collected over Baseline (Day 0) up to end of study (up to 12.9 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hemophilia A Group | 0/50 (0%) | 0/50 (0%) | 6/50 (12%) |
| Event | Hemophilia A Group |
|---|---|
| PyrexiaGeneral disorders | 2/50 |
| Skin lacerationInjury, poisoning and procedural complications | 2/50 |
| VaricellaInfections and infestations | 1/50 |
| Animal biteInjury, poisoning and procedural complications | 1/50 |
| Joint injuryInjury, poisoning and procedural complications | 1/50 |
Effectiveness Full Analysis Set (EFAS) comprised of all participants for whom all inclusion and none of the exclusion criteria were met.
| Age, Continuous(years) | Hemophilia A Group |
|---|---|
| Mean | 19.5 ± 13.01 |
| Sex: Female, Male(Participants) | Hemophilia A Group |
|---|---|
| Female | 0 |
| Male | 50 |
| Ethnicity (NIH/OMB)(Participants) | Hemophilia A Group |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 50 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Hemophilia A Group |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 50 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Hemophilia A Group |
|---|---|
| India | 50 |
| Weight(kilograms (kg)) | Hemophilia A Group |
|---|---|
| Mean | 48.5 ± 20.95 |
| Height(centimeters (cm)) | Hemophilia A Group |
|---|---|
| Mean | 152.0 ± 22.68 |
| Body Mass Index (BMI)(kilograms per meter square (kg/m^2)) | Hemophilia A Group |
|---|---|
| Mean | 19.9 ± 5.42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2022 to primary completion in Feb 2023, 12 months.
Results were first posted in Mar 2024, 1 year after primary completion.
Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Antihemophilic factor, human recombinant